On May 30, 2025, Wells Fargo’s analyst Brandon Couillard announced the initiation of coverage on Bio-Techne (TECH, Financial) with an "Overweight" rating. This new rating reflects Wells Fargo's positive outlook on TECH, indicating expectations of the stock outperforming market averages.
Furthermore, Wells Fargo set a price target of USD 59.00 for Bio-Techne (TECH, Financial). The announcement marks the first coverage by Wells Fargo for TECH, with no prior ratings or price targets set.
Investors and stakeholders in Bio-Techne (TECH, Financial) are advised to take note of this recent analysis from Wells Fargo as it may influence future stock performance and market perception.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for Bio-Techne Corp (TECH, Financial) is $70.36 with a high estimate of $90.00 and a low estimate of $51.00. The average target implies an upside of 45.59% from the current price of $48.33. More detailed estimate data can be found on the Bio-Techne Corp (TECH) Forecast page.
Based on the consensus recommendation from 16 brokerage firms, Bio-Techne Corp's (TECH, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Bio-Techne Corp (TECH, Financial) in one year is $85.55, suggesting a upside of 77.01% from the current price of $48.33. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Bio-Techne Corp (TECH) Summary page.
